What are CJC-1295 and ipamorelin?
Both are synthetic peptides studied for their ability to raise the body's own growth-hormone (GH) output, rather than supplying GH directly the way somatropin does. That shared goal is why they are so often discussed in the same breath — but they get there through different machinery.
CJC-1295 is an analog of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on the anterior pituitary and prompts the gland to release GH. The widely circulated "with DAC" version adds a Drug Affinity Complex that tethers the peptide to blood albumin, stretching its half-life to roughly 6-8 days; the bare "modified GRF(1-29)" version is far shorter-acting.
Ipamorelin is a small, 5-amino-acid peptide that works on a completely different receptor — the ghrelin receptor, or GHS-R1a, the same one the hunger hormone ghrelin uses. It is described as "selective" because, in the studies that exist, it raised GH without meaningfully bumping cortisol or prolactin, which was the trouble with some older GH-releasing peptides.
Crucially, neither is an approved medicine. Both are sold as research chemicals labeled not for human use. Both were placed on the FDA's interim Category 2 bulk-substance list in 2023, then removed from that list in 2024 pending a formal compounding review — a procedural change that is not the same as approval. They remain unapproved drugs.
How do the two mechanisms differ — and why are they combined?
The cleanest way to think about it: CJC-1295 works "upstream" on the GHRH receptor, while ipamorelin works on the parallel ghrelin/GHS-R1a receptor. Because these are two distinct receptors that both feed into GH release, the rationale offered for pairing them is that each pushes a different lever at the same time.
There is a duration mismatch worth understanding. CJC-1295 with DAC is built to act for days, producing a sustained elevation in GHRH signaling. Ipamorelin is the opposite — short and pulsatile, with a roughly 2-hour half-life, producing a brief spike of GH release. So they are not interchangeable: one is a long, steady background signal and the other is a short prompt.
It is important to be candid here: while the single-compound pharmacology is reasonably described in early human studies, the popular idea that combining them is safe or produces a specific clinical benefit is not something controlled human trials have established. The combination narrative rests largely on mechanism and on uncontrolled use, not on trial evidence.
What does the human evidence actually show?
This is where the gap between marketing and data is widest, so it deserves a direct answer. For CJC-1295, the most-cited human study (Teichman 2006) gave it to healthy adults and measured the hormonal response: mean GH rose roughly 2- to 10-fold, and IGF-I (a downstream marker) rose about 1.5- to 3-fold, with the long half-life confirmed. That demonstrates the peptide moves the hormones it is supposed to move — but it is a pharmacology study in healthy volunteers, not evidence of a clinical benefit, and development did not advance to large Phase 3 trials.
For ipamorelin, the furthest it reached in humans is instructive. A Phase 2, randomized, placebo-controlled trial tested it for postoperative ileus (slowed gut function after bowel surgery). The result: it was well tolerated, but it did not hit its primary endpoint — median time to a first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, a difference that was not statistically significant (p=0.15). The program was not carried forward.
The honest takeaway: both compounds have some human pharmacology data, but neither has demonstrated a proven clinical benefit in an adequately powered trial, and neither earned an approval. Claims about body composition, recovery, or anti-aging in people remain unproven.
Are they legal, and what about drug testing?
Neither CJC-1295 nor ipamorelin is approved by the FDA for human use; both are research-use-only. Their status on the FDA compounding lists has shifted — added to Category 2 in 2023, removed in 2024 pending an advisory-committee review — but at no point did that make them approved drugs, and the FDA has signaled it does not favor adding them to the permitted compounding list.
For anyone in tested sport, the line is clear and strict: both fall under Section S2 of the World Anti-Doping Agency Prohibited List (peptide hormones, growth factors, and GH secretagogues), prohibited at all times — in and out of competition. Modern assays can detect GH-releasing peptides at very low concentrations, and a positive test is an anti-doping rule violation. Treat both as disqualifying in any drug-tested context.
Tracking either compound on PeptidePanel
PeptidePanel does not sell, source, supply, endorse, or prescribe any compound, and nothing here is medical advice. Both peptides on this page are unapproved and of unproven benefit and safety in humans.
If you are working with a qualified clinician who is monitoring an experimental protocol, the monitoring discipline is what reduces risk: logging doses, watching the relevant bloodwork (for GH-axis peptides that typically means IGF-1, fasting glucose, and HbA1c), and documenting any side effects early. PeptidePanel is the neutral tracking layer for exactly that — it records the protocol your clinician sets and charts your labs against reference ranges. The decision to use any investigational compound belongs with a licensed physician who understands the risks.